Small Cell Lung Cancer
8 competing products in clinical development for Small Cell Lung Cancer.
Pipeline by Phase
Pre-clinical1
Phase 11
Phase 1/23
Phase 22
Phase 31
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ifinatamab deruxtecan + Topotecan + Amrubicin + Lurbinectedin | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Gocatamig + Ifinatamab Deruxtecan (I-DXd) + Durvalumab | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |
| Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd) | Daiichi Sankyo | Phase 1/2 | Active | 36 |
| Prexasertib | Eli Lilly | Phase 2 | Completed | 35 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | Completed | 29 |
| Pemetrexed | Eli Lilly | Phase 2 | Terminated | 27 |
| CPT-11 + Platinum analogues | Daiichi Sankyo | Pre-clinical | Completed | 26 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | Terminated | 24 |